Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six brokerages that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $5.17.

SGMO has been the subject of several recent research reports. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Truist Financial lowered their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a report on Thursday, January 23rd. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th.

Hedge Funds Weigh In On Sangamo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC boosted its position in Sangamo Therapeutics by 14.6% during the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company's stock valued at $1,853,000 after buying an additional 272,123 shares during the period. Virtu Financial LLC bought a new stake in shares of Sangamo Therapeutics in the 3rd quarter valued at about $150,000. Shelton Wealth Management LLC purchased a new stake in Sangamo Therapeutics during the 4th quarter valued at about $29,000. Golden State Equity Partners grew its position in Sangamo Therapeutics by 2,592.3% during the 4th quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company's stock worth $332,000 after acquiring an additional 313,587 shares during the last quarter. Finally, Sageworth Trust Co purchased a new position in Sangamo Therapeutics in the 4th quarter worth approximately $61,000. Institutional investors own 56.93% of the company's stock.

Sangamo Therapeutics Stock Down 2.7 %

Sangamo Therapeutics stock traded down $0.02 during midday trading on Monday, reaching $0.70. The stock had a trading volume of 1,377,027 shares, compared to its average volume of 8,591,472. The firm has a market capitalization of $160.53 million, a PE ratio of -0.93 and a beta of 1.46. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18. The firm's 50-day moving average price is $0.78 and its 200 day moving average price is $1.37.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The business had revenue of $7.55 million during the quarter, compared to the consensus estimate of $11.70 million. Equities research analysts expect that Sangamo Therapeutics will post -0.46 EPS for the current year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.